Emergent BioSolutions Full Year 2022 Earnings: Revenues Beat Expectations, EPS Lags

·1-min read

Emergent BioSolutions (NYSE:EBS) Full Year 2022 Results

Key Financial Results

  • Revenue: US$1.12b (down 38% from FY 2021).

  • Net loss: US$223.8m (down by 197% from US$230.9m profit in FY 2021).

  • US$4.47 loss per share (down from US$4.32 profit in FY 2021).


All figures shown in the chart above are for the trailing 12 month (TTM) period

Emergent BioSolutions Revenues Beat Expectations, EPS Falls Short

Revenue exceeded analyst estimates by 3.0%. Earnings per share (EPS) missed analyst estimates by 7.5%.

Looking ahead, revenue is expected to decline by 1.8% p.a. on average during the next 3 years, while revenues in the Biotechs industry in the US are expected to grow by 15%.

Performance of the American Biotechs industry.

The company's shares are down 11% from a week ago.

Risk Analysis

What about risks? Every company has them, and we've spotted 1 warning sign for Emergent BioSolutions you should know about.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Join A Paid User Research Session
You’ll receive a US$30 Amazon Gift card for 1 hour of your time while helping us build better investing tools for the individual investors like yourself. Sign up here